CCR9 as a prognostic marker and therapeutic target in hepatocellular carcinoma

Oncology Reports

Volumn 31, Issue 4, 2014, Pages 1629-1636

  Zhang, Zhenhai ^a   Qin, Chengkun ^a   Wu, Yaguang ^a   Su, Zhongxue ^a   Xian, Guozhe ^a   Hu, Bo ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

CCR9; Hepatocellular carcinoma; Marker; Prognosis; Therapeutic target

Indexed keywords

CHEMOKINE RECEPTOR CCR9; CYCLIN D1; PROTEIN P21; PROTEIN P27;

ADULT; AGED; ARTICLE; BRDU ASSAY; CANCER PROGNOSIS; CARCINOGENICITY; CELL CYCLE; CELL PROLIFERATION; CLINICAL EVALUATION; CLINICAL FEATURE; COLONY FORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MTT ASSAY; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; TUMOR INVASION; UPREGULATION; WESTERN BLOTTING;

ADULT; AGED; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CCR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84908135144     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.2998     Document Type: Article

References (22)

1. Zhu AX, Duda DG, Sahani DV and Jain RK: HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 8: 292-301, 2011.
2. Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A and Montalto G: Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 3: 236-260, 2012.
3. McClune AC and Tong MJ: Chronic hepatitis B and hepatocellular carcinoma. Clin Liver Dis 14: 461-476, 2010.
4. Finn RS: Emerging targeted strategies in advanced hepatocellular carcinoma. Semin Liver Dis 33 (Suppl 1): S11-S19, 2013.
5. Zhou L, Liu J and Luo F: Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 12: 1175-1181, 2006.
6. Psyrri A, Arkadopoulos N, Vassilakopoulou M, Smyrniotis V and Dimitriadis G: Pathways and targets in hepatocellular carcinoma. Expert Rev Anticancer Ther 12: 1347-1357, 2012.
7. Viola A and Luster AD: Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol 48: 171-197, 2008.
8. Franciszkiewicz K, Boissonnas A, Boutet M, Combadière C and Mami-Chouaib F: Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Res 72: 6325-6332, 2012.
9. Svensson M and Agace WW: Role of CCL25/CCR9 in immune homeostasis and disease. Expert Rev Clin Immunol 2: 759-773, 2006.
10. Shen X, Mailey B, Ellenhorn JD, Chu PG, Lowy AM and Kim J: CC chemokine receptor 9 enhances proliferation in pancreatic intraepithelial neoplasia and pancreatic cancer cells. J Gastrointest Surg 13: 1955-1962, 2009.
11. Johnson-Holiday C, Singh R, Johnson E, et al: CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion. Int J Oncol 38: 1279-1285, 2011.
12. Geisler SA, Olshan AF, Weissler MC, et al: p16 and p53 protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin Cancer Res 8: 3445-3453, 2000.
13. Fukuoka J, Fuji T, Shih JH, et al: Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin Cancer Res 10: 4314-4324, 2004.
14. Cao Z, Zhang R, Li J, et al: X-linked inhibitor of apoptosis protein (XIAP) regulation of cyclin D1 protein expression and cancer cell anchorage-independent growth via its E3 ligase-mediated protein phosphatase 2A/c-Jun axis. J Biol Chem 288: 20238-20247, 2013.
15. Ye QH, Qin LX, Forgues M, et al: Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9: 416-423, 2003.
16. Yu Y, Kovacevic Z and Richardson DR: Tuning cell cycle regulation with an iron key. Cell Cycle 6: 1982-1994, 2007.
17. Macaluso M, Montanari M, Cinti C and Giordano A: Modulation of cell cycle components by epigenetic and genetic events. Semin Oncol 32: 452-457, 2005.
18. Nakamoto N, Ebinuma H, Kanai T, et al: CCR9+ macrophages are required for acute liver inflammation in mouse models of hepatitis. Gastroenterology 142: 366-376, 2012.
19. Chu PS, Nakamoto N, Ebinuma H, et al: C-C motif chemokine receptor 9 positive macrophages activate hepatic stellate cells and promote liver fibrosis in mice. Hepatology 58: 337-350, 2013.
20. Amersi FF, Terando AM, Goto Y, et al: Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin Cancer Res 14: 638-645, 2008.
21. Johnson EL, Singh R, Singh S, et al: CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion. World J Surg Oncol 8: 62, 2010.
22. Singh S, Singh UP, Stiles JK, Grizzle WE and Lillard JW Jr: Expression and functional role of CCR9 in prostate cancer cell migration and invasion. Clin Cancer Res 10: 8743-8750, 2004.